Patents by Inventor Cynthia Shafer
Cynthia Shafer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100003246Abstract: New substituted heterocyclic compounds, compositions containing them, and methods of using them for the inhibition of Raf kinase activity are provided. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: ApplicationFiled: March 19, 2009Publication date: January 7, 2010Inventors: Zilin Hunag, Jeff Jin, Timothy Machajewski, William R. Antonios-McCrea, Maureen McKenna, Daniel Poon, Paul A. Renhowe, Martin Sendzik, Cynthia Shafer, Aaron Smith, Yongjin Xu, Qiong Zhang, Zheng Chen
-
Patent number: 7642278Abstract: Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.Type: GrantFiled: October 27, 2005Date of Patent: January 5, 2010Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Johanna M. Jansen, Christopher McBride, Paul A. Renhowe, Cynthia Shafer
-
Publication number: 20090170904Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: ApplicationFiled: December 5, 2008Publication date: July 2, 2009Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
-
Patent number: 7482367Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: GrantFiled: August 30, 2006Date of Patent: January 27, 2009Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: Mina E. Aikawa, Payman Amiri, Jeffrey H. Dove, Barry Haskell Levine, Christopher McBride, Teresa E. Pick, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
-
Patent number: 7368459Abstract: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.Type: GrantFiled: October 11, 2006Date of Patent: May 6, 2008Assignee: Chiron CorporationInventors: Paul A. Renhowe, Timothy Machajewski, Cynthia Shafer, Mary Ellen Wernette Hammond, Sabina Pecchi
-
Publication number: 20080070906Abstract: Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: ApplicationFiled: October 2, 2007Publication date: March 20, 2008Inventors: Paul Renhowe, Sabina Pecchi, Timothy Machajewski, Cynthia Shafer, Clarke Taylor, William McCrea, Christopher McBride, Elisa Jazan
-
Publication number: 20070299039Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: ApplicationFiled: November 18, 2005Publication date: December 27, 2007Applicant: Chiron CorporationInventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Levine, Christopher McBride, Daniel Poon, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Sharadha Subramanian, Leonard Sung
-
Publication number: 20070293491Abstract: New compounds capable of acting as CDC7 inhibitors are provided. The compounds are useful either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of CDC7 mediated diseases, such as cancer. The compounds have the Formula (I) or (II), where the values of the variables are defined herein.Type: ApplicationFiled: April 13, 2007Publication date: December 20, 2007Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.Inventors: Cynthia Shafer, Annette Walter, Mika Lindvall, Thomas Gesner, Laura Doyle
-
Publication number: 20070161680Abstract: New substituted benzimidazole compounds, compositions, and methods of inhibition of kinase activity associated with tumorigenesis in a human or animal subject are provided. In certain embodiments, the compounds and compositions are effective to inhibit the activity of at least one serine/threonine kinase or receptor tyrosine kinase. The new compounds and compositions may be used either alone or in combination with at least one additional agent for the treatment of a serine/threonine kinase- or receptor tyrosine kinase-mediated disorder, such as cancer.Type: ApplicationFiled: August 30, 2006Publication date: July 12, 2007Inventors: Mina Alkawa, Payman Amiri, Jeffrey Dove, Barry Levine, Christopher McBride, Teresa Pick, Daniel Poon, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Darrin Stuart, Sharadha Subramanian
-
Publication number: 20070123546Abstract: Disclosed are 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, their stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Disclosed also are methods of using the 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cellular proliferative, viral, autoimmune, cardiovascular, and central nervous system diseases.Type: ApplicationFiled: September 28, 2006Publication date: May 31, 2007Inventors: Timothy Machajewski, Cynthia Shafer, Christopher McBride, William Antonios-McCrea, Brandon Doughan, Barry Levine, Yi Xia, Maureen McKeena, X. Wang, Kris Mendenhall, Yasheen Zhou, Baoquing Gong, Dan Gu, John Dolan, John Tulinsky, Kristin Brinner, Zhenhai Gao
-
Publication number: 20070032528Abstract: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.Type: ApplicationFiled: October 11, 2006Publication date: February 8, 2007Inventors: Paul Renhowe, Timothy Machajewski, Cynthia Shafer, Mary Ellen Hammond, Sabina Pecchi
-
Publication number: 20070027150Abstract: 2-Amino-quinazolin-5-one compounds, stereoisomers, tautomers, pharmaceutically acceptable salts, and prodrugs thereof; compositions that include a pharmaceutically acceptable carrier and one or more of the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent. Methods of using the 2-amino-quinazolin-5-one compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of cell proliferative diseases.Type: ApplicationFiled: April 14, 2006Publication date: February 1, 2007Inventors: Cornelia Bellamacina, Abran Costales, Brandon Doughan, Susan Fong, Zhenhai Gao, Thomas Hendrickson, Barry Levine, Xiaodong Lin, Timothy Machajewski, Christopher McBride, William Antonios-McCrea, Maureen McKenna, Kris Mendenhall, Alice Rico, Cynthia Shafer, X. Wang, Yi Xia, Yasheen Zhou
-
Patent number: 7138409Abstract: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.Type: GrantFiled: April 14, 2004Date of Patent: November 21, 2006Assignee: Chiron CorporationInventors: Paul A. Renhowe, Timothy Machajewski, Cynthia Shafer, Mary Ellen Wernette Hammond, Sabina Pecchi
-
Publication number: 20060079564Abstract: Organic compounds having the structure I are provided where the variables have the values described herein. A method of inhibiting c-ABL in a patient includes administering an effective amount of a compound of structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compound, or a pharmaceutically acceptable salt of the tautomer to the patient.Type: ApplicationFiled: October 27, 2005Publication date: April 13, 2006Inventors: Johanna Jansen, Christopher McBride, Paul Renhowe, Cynthia Shafer
-
Publication number: 20050209456Abstract: A method for synthesizing a 4-amino substituted quinolinone includes reacting a substituted or unsubstituted 2-benzimidazolyl-2-acetate with a substituted or unsubstituted 2-aminobenzonitrile in the presence of a base or an acid. A 4-amino substituted quinolinone compound is formed by the reaction, and the 4-amino substituted quinolinone compound comprises a benzimidazole group.Type: ApplicationFiled: March 29, 2005Publication date: September 22, 2005Inventors: Paul Renhowe, Cynthia Shafer, Timothy Machajewski, Sabina Pecchi, Christopher McBride
-
Publication number: 20050203101Abstract: Methods of treating cancer include contacting a cancer cell with 4-amino-5-fluoro-3-(5-piperazin-1-yl-1H-benzimidazol-2-yl)quinolin-2(1H)-one, 4-amino-5-fluoro-3-[5-(4-methyl-4-oxidopiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one, tautomers thereof, pharmaceutically acceptable salts thereof, pharmaceutically acceptable salts of the tautomers thereof, or a mixture thereof.Type: ApplicationFiled: May 5, 2004Publication date: September 15, 2005Inventors: Paul Barsanti, Dirksen Bussiere, Stephen Harrison, Carla Heise, Johanna Jansen, Elisa Jazan, Timothy Machajewski, Christopher McBride, William McCrea, Simon Ng, Zhi-Jie Ni, Sabina Pecchi, Keith Pfister, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Joel Silver, Allan Wagman, Marion Wiesmann, Kelly Wayman
-
Publication number: 20050192287Abstract: New substituted benzazole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.Type: ApplicationFiled: October 15, 2004Publication date: September 1, 2005Applicant: Chiron CorporationInventors: Abran Costales, Teresa Hansen, Barry Levine, Christopher McBride, Daniel Poon, Savithri Ramurthy, Paul Renhowe, Cynthia Shafer, Sharadha Subramanian, Joelle Verhagen
-
Publication number: 20050137188Abstract: Organic compounds having the structural formula I are provided where the variables have the values described herein and R1 and R2 join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.Type: ApplicationFiled: April 14, 2004Publication date: June 23, 2005Inventors: Paul Renhowe, Timothy Machajewski, Cynthia Shafer, Mary Wernette Hammond, Sabina Pecchi
-
Publication number: 20050054672Abstract: Organic compounds having the formula I are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.Type: ApplicationFiled: July 8, 2004Publication date: March 10, 2005Inventors: Paul Renhowe, Sabina Pecchi, Timothy Machajewski, Cynthia Shafer, Clarke Taylor, William McCrea, Christopher McBride, Elisa Jazan